Clinical Trials Logo

Clinical Trial Summary

Major depressive disorder (MDD) is a leading cause of disability worldwide. Up to 50% of patients experience treatment resistant depression (TRD), which accounts for a vast majority of disease burden. Current medications for TRD have limited efficacy and can be associated with intolerable side effects. Therefore, there is a need for finding new treatment targets. Accumulating evidence suggests some patients with MDD including those with TRD, display brain inflammation. Thus, patients with TRD may benefit from medications that can reduce this inflammation. Minocycline is an antibiotic which can cross the blood-brain barrier and has effects on several systems implicated in depression. The principal investigator led the first pilot study of minocycline as an add-on treatment in TRD demonstrating that it led to a significant reduction in depressive symptoms compared to placebo and these findings require replication in a larger sample to confirm the efficacy and tolerability of this treatment approach.

This study is a 12 week, double-blind, placebo-controlled trial of minocycline as add-on treatment for patients suffering from a major depressive episode who have failed to respond to at least two adequate trials of antidepressant treatment. After screening and randomization to the two parallel arms of the trial, 50 patients will receive minocycline added to treatment as usual (TAU) and 50 patients will receive placebo added to TAU. Clinical assessment will include the Hamilton Depression Rating Scale (HAMD-17), Clinical Global Impression scale (CGI), Patient Health Questionnaire (PHQ-9), and the Generalized Anxiety Disorder scale (GAD-7) at each study visit (screening, baseline, week 2, 6, and 12). Side effects checklists will be undertaken at each visit. Minocycline will be started at 100 mg once daily and will be increased to 100 mg twice daily at two weeks. Secondary outcomes include inflammatory biomarkers measured at baseline, weeks 6 and 12.

This trial will provide further evidence of minocycline's efficacy and acceptability as a treatment option for patients with TRD and provide insights into its mechanism of action.

Clinical Trial Description


Study Design

Related Conditions & MeSH terms

NCT number NCT03947827
Study type Interventional
Source Centre for Addiction and Mental Health
Contact Tania Jain
Phone 416-535-8501
Status Not yet recruiting
Phase Phase 3
Start date August 2019
Completion date August 2021

See also
  Status Clinical Trial Phase
Active, not recruiting NCT02935595 - Low Dose Intravenous Ketamine in Treatment Resistant Depression Patients Phase 2
Enrolling by invitation NCT03134066 - Neurocognitive Features of Patients With Treatment-Resistant Depression
Recruiting NCT01984710 - DBS for TRD Medtronic Activa PC+S N/A
Completed NCT01935115 - Comparing Ketamine and Propofol Anesthesia for Electroconvulsive Therapy Phase 4
Terminated NCT01687478 - A Study of Olanzapine and Fluoxetine for Treatment-resistant Depression Phase 3
Completed NCT00531726 - Berlin Deep Brain Stimulation Depression Study N/A
Recruiting NCT03272698 - ECT With Ketamine Anesthesia vs High Intensity Ketamine With ECT Rescue for Treatment-Resistant Depression Phase 4
Recruiting NCT03288675 - Stepped Care aiTBS 2 Depression Study (Ghent) N/A
Terminated NCT02675556 - Allogeneic Human Mesenchymal Stem Cells (hMSCs) Infusion in Patients With Treatment Resistant Depression Phase 1
Recruiting NCT03428828 - Neurofeedback for Treatment Resistant Depression N/A
Recruiting NCT03711019 - Efficacy of Convulsive Therapies During Continuation N/A
Recruiting NCT02611206 - Repetitive Transcranial Magnetic Stimulation for Adolescent Depression: Efficacy, Predictive Biomarkers, and Mechanisms N/A
Active, not recruiting NCT00565617 - Epidural Cortical Stimulation for Depression N/A
Recruiting NCT03742557 - Evaluation of Schemes of Administration of Intravenous Ketamine in Depression Phase 3
Withdrawn NCT03290963 - Effect of Lithium Versus Placebo in Adults With Treatment-Resistant Depression Who Are Receiving Ketamine Phase 2
Recruiting NCT02046330 - Deep Brain Stimulation (DBS) Therapy for Treatment Resistant Depression N/A
Completed NCT01246908 - Efficacy, Safety and Tolerability of CX157 in Treatment Resistant Depression Phase 2
Completed NCT00789854 - Comparing Quetiapine XR Monotherapy and Augmentation With Lithium Augmentation in TRD Patients Phase 3
Recruiting NCT03152409 - Salicylic Augmentation in Depression Phase 2
Recruiting NCT03515733 - PF-04995274 and Emotional Processing in Treatment Resistant Depression Phase 1